NKTR Nektar Therapeutics

34.62
+0.73  (+2%)
Previous Close 33.89
Open 34.06
Price To Book 3.69
Market Cap 6,034,508,167
Shares 174,306,995
Volume 1,418,725
Short Ratio
Av. Daily Volume 1,630,267

NewsSee all news

  1. Is Nektar Therapeutics (NKTR) A Good Stock To Buy?
  2. Nektar's Drug Could be a "Big Deal"
  3. Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics
  4. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  5. Should We Be Delighted With Nektar Therapeutics's (NASDAQ:NKTR) ROE Of 40%?

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated melanoma data June 1, 2019 noted ORR was 53% (34% CR);.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 commencement of dosing announced September 12, 2017. Initial data presented at ASCO 2018
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
PDUFA date extended three months to August 29, 2019.
NKTR-181
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1/2 initial data March 1, 2019 noted ORR 2/11 ( 18%) - maximum tolerated dose has not been reached.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b data presented at EULAR June 13, 2019 - safe and well-tolerated.
NKTR-358
Systemic lupus erythematosus (SLE)
Phase 2 data presented at ASCO June 3, 2019.
NKTR-214 and nivolumab
Sarcomas

Latest News

  1. Is Nektar Therapeutics (NKTR) A Good Stock To Buy?
  2. Nektar's Drug Could be a "Big Deal"
  3. Harry Boxer’s three biotech stocks on the move include Nektar Therapeutics
  4. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  5. Should We Be Delighted With Nektar Therapeutics's (NASDAQ:NKTR) ROE Of 40%?
  6. 3 Big Stock Charts for Friday: Symantec, Vertex Pharmaceuticals and Nektar Therapeutics
  7. The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes
  8. Edited Transcript of NKTR earnings conference call or presentation 8-May-19 9:00pm GMT
  9. Nektar Therapeutics to Host Webcast Conference Call with Immunology Expert for Analysts & Investors During 2019 European Congress of Rheumatology (EULAR 2019)
  10. Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
  11. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  12. Nektar (NKTR) Down 7% Since Last Earnings Report: Can It Rebound?
  13. Cancer-Fighting Stocks & ETF: What You Need to Know
  14. Nektar (NKTR) in Focus: Stock Moves 8.8% Higher
  15. Why El Paso Electric, Nektar Therapeutics, and Hecla Mining Jumped Today
  16. Who Are The Winners And Losers From The Year's Biggest Cancer Meeting?
  17. Why Cancer-Fighting Stocks & ETFs Are Soaring
  18. Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study
  19. Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting
  20. How To Know What’s In Your ETF